Givlaari® (Givosiran) – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers Givlaari (givosiran) for adults with acute hepatic porphyrias (AHP) but excludes patients with prior liver transplant and prohibits concomitant prophylactic hemin while on therapy. Coverage requires a documented AHP diagnosis plus either ≥2 porphyria attacks in the past 6 months or current prophylactic hemin use with provider attestation, prescribing/consultation by a hematologist or AHP specialist, FDA‑label dosing (2.5 mg/kg SC monthly) with documented body weight and attack/hemin history, authorizations limited to 12 months, and reauthorization only with evidence of clinical benefit.

"Treatment of acute hepatic porphyrias (AHP)."

Sign up to see full coverage criteria, indications, and limitations.